Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
You may also be interested in...
Since using a reverse-merger last year to go public, Kura Oncology has resurrected an abandoned Janssen cancer candidate and raised $46.5m in an IPO. CEO Troy Wilson spoke with Scrip about the firm's efforts toward precision medicine in cancer.
Kura Oncology raised $60m in a private placement and plans to complete a reverse merger into a public company to support Phase II clinical trials for tipifarnib, a drug for which Johnson & Johnson's Janssen subsidiary suspended development in multiple cancer indications in 2008.
Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”